161 related articles for article (PubMed ID: 21958699)
1. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.
Mou S; Wang Q; Li J; Shi B; Ni Z
Clin Chim Acta; 2012 Jan; 413(1-2):187-91. PubMed ID: 21958699
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
[TBL] [Abstract][Full Text] [Related]
3. Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury.
Manabe K; Kamihata H; Motohiro M; Senoo T; Yoshida S; Iwasaka T
Eur J Clin Invest; 2012 May; 42(5):557-63. PubMed ID: 22070248
[TBL] [Abstract][Full Text] [Related]
4. Urinary fatty acid binding protein in renal disease.
Kamijo-Ikemori A; Sugaya T; Kimura K
Clin Chim Acta; 2006 Dec; 374(1-2):1-7. PubMed ID: 16860300
[TBL] [Abstract][Full Text] [Related]
5. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Inoue T; Node K
Am J Nephrol; 2006; 26(1):82-6. PubMed ID: 16534182
[TBL] [Abstract][Full Text] [Related]
6. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
[TBL] [Abstract][Full Text] [Related]
7. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
Nakamura T; Sugaya T; Node K; Ueda Y; Koide H
Am J Kidney Dis; 2006 Mar; 47(3):439-44. PubMed ID: 16490622
[TBL] [Abstract][Full Text] [Related]
8. Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.
Nakamura T; Sugaya T; Ebihara I; Koide H
Am J Nephrol; 2005; 25(5):447-50. PubMed ID: 16118482
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis.
Idasiak-Piechocka I; Oko A; Pawliczak E; Kaczmarek E; Czekalski S
Nephrol Dial Transplant; 2010 Dec; 25(12):3948-56. PubMed ID: 20525973
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic implications of urinary liver-type fatty acid-binding protein and 8-hydroxy-2'-deoxyguanosine in forensic autopsy cases.
Kashiwagi M; Sugimura T; Matsusue A; Hara K; Waters B; Kubo S
Leg Med (Tokyo); 2013 May; 15(3):140-4. PubMed ID: 23273867
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
12. [Clinical implication of urine test for markers of endothelial dysfunction and angiogenesis factors in assessment of tubulointerstitial fibrosis in chronic glomerulonephritis].
Bobkova IN; Kozlovskaia LV; Rameeva AS; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2007; 79(6):10-5. PubMed ID: 17684960
[TBL] [Abstract][Full Text] [Related]
13. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K
Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
[TBL] [Abstract][Full Text] [Related]
14. Urinary liver type fatty acid binding protein in diabetic nephropathy.
Kamijo-Ikemori A; Sugaya T; Ichikawa D; Hoshino S; Matsui K; Yokoyama T; Yasuda T; Hirata K; Kimura K
Clin Chim Acta; 2013 Sep; 424():104-8. PubMed ID: 23727660
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the measurements of urinary liver-type fatty acid binding protein levels in patients with acute coronary syndrome.
Matsumori R; Shimada K; Kiyanagi T; Hiki M; Fukao K; Hirose K; Ohsaka H; Miyazaki T; Kume A; Yamada A; Takagi A; Ohmura H; Miyauchi K; Daida H
J Cardiol; 2012 Sep; 60(3):168-73. PubMed ID: 22658694
[TBL] [Abstract][Full Text] [Related]
16. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.
Kamijo A; Sugaya T; Hikawa A; Yamanouchi M; Hirata Y; Ishimitsu T; Numabe A; Takagi M; Hayakawa H; Tabei F; Sugimoto T; Mise N; Omata M; Kimura K
Mol Cell Biochem; 2006 Mar; 284(1-2):175-82. PubMed ID: 16532260
[TBL] [Abstract][Full Text] [Related]
17. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients.
Niizeki T; Takeishi Y; Arimoto T; Takabatake N; Nozaki N; Hirono O; Watanabe T; Nitobe J; Harada M; Suzuki S; Koyama Y; Kitahara T; Sasaki T; Kubota I
J Card Fail; 2007 Mar; 13(2):120-7. PubMed ID: 17395052
[TBL] [Abstract][Full Text] [Related]
18. [L-type fatty acid binding protein (L-FABP) and kidney disease].
Kamijo-Ikemori A; Sugaya T; Kimura K
Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492
[TBL] [Abstract][Full Text] [Related]
19. Urinary liver-type fatty acid-binding protein linked with increased risk of acute kidney injury after allogeneic stem cell transplantation.
Shingai N; Morito T; Najima Y; Igarashi A; Kobayashi T; Doki N; Kakihana K; Ohashi K; Ando M
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2010-4. PubMed ID: 25193082
[TBL] [Abstract][Full Text] [Related]
20. [Urine excretion of a monocytic chemotaxic protein-1 and a transforming growth factor beta1 as an indicator of chronic glomerulonephritis progression].
Bobkova IN; Chebotareva NV; Kozlovskaia LV; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2006; 78(5):9-14. PubMed ID: 16889042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
